
Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients
BOSTON--(BUSINESS WIRE)--A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries.
Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting—seven saw an increase in patient out-of-pocket costs.
Share
The IRA Medicare Drug Access Tracker, developed by Dr. William Smith and Dr. Robert Popovian, monitors the impact of the Inflation Reduction Act's (IRA) drug pricing provisions. Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting— seven saw an increase in patient out-of-pocket costs. (The insulin product was not studied since its price was fixed in statute under a separate IRA provision.)
'The price controls show that Congress fundamentally doesn't understand the rebate system that underpins the pharmaceutical market,' said Dr. William Smith, who built the Tracker with Dr. Robert Popovian. 'All the politicians who argued that the IRA law would make drugs more affordable should look at this new data.'
Under the current system, drug manufacturers pay substantial rebates to pharmacy benefit managers (PBMs) such as Caremark and Optum. These rebates help offset costs but are invisible to patients. When CMS seeks to control prices by lowering a drug's official 'list price,' as it does with the anti-coagulant Eliquis —bringing the price down from $521 to $231—rebates disappear, likely eliminating hundreds of millions in rebate payments from manufacturers to PBMs. PBMs appear to be compensating for that loss by raising co-pays, co-insurance, and transferring other charges directly to patients.
The IRA Medicare Drug Access Tracker focuses on Medicare patients served by the four largest PBMs, which account for 87 percent of the market. The tool is designed to measure whether federal price controls actually improve affordability for seniors by tracking out-of-pocket costs over time. It also follows administrative burdens that PBMs may have imposed on these drugs, which may strain already short-staffed providers, such as requiring them to fill out additional paperwork to secure a prescription (prior authorization) or placing quantity limits on the medications. Such administrative burdens are often used in the industry to discourage demand (demand management).
Among the Tracker's key findings:
Average out-of-pocket costs for the nine drugs rose 32 percent, from $74.51 to $98.42
Seven of the nine drugs saw individual cost increases ranging from $10.56 to $316.81
One of the two medicines seeing no increase in out-of-pocket costs faced competition from biosimilars that only became available in 2025
'Higher out-of-pocket costs are unlikely to be the only unintended consequence of drug price controls,' Dr. Popovian said. 'The IRA also creates less incentive for pharmaceutical innovation and increases the possibility that some popular drugs may be excluded from health insurance formularies.'
This release marks the Tracker's first report. Pioneer Institute will publish additional data later this year, as more drugs fall under the Inflation Reduction Act's price-setting provisions.
The public can find the tool at https://pioneerinstitute.org/rxpricewatch/
Dr. William S. Smith is Senior Fellow & Director of Pioneer Life Sciences Initiative. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor's office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer's corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.
Dr. Robert Popovian is the Founder of the strategic consulting firm Conquest Advisors. He also serves as Chief Science Policy Officer at the Global Healthy Living Foundation, Senior Healthy Policy Fellow at the Progressive Policy Institute, and Visiting Health Policy Fellow at the Pioneer Institute. He previously served as Vice President, U.S. Government Relations at Pfizer.
One of the country's foremost experts on every significant facet of biopharmaceuticals and the healthcare industry, he is a recognized authority on health economics, policy, government relations, medical affairs, and strategic planning. To learn more about Dr. Popovian please click here.
About Pioneer Institute
Pioneer empowers Americans with choices and opportunities to live freely and thrive. Working with state policymakers, we use expert research, educational initiatives, legal action and coalition-building to advance human potential in four critical areas: K-12 Education, Health, Economic Opportunity, and American Civic Values.
Please see below the first group of drugs subject that Pioneer is studying.
Eliquis
Enbrel
Entresto
Farxiga
Imbruvica
Januvia
Jardiance
Stelara
Xarelto
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
UnitedHealth Seeks $1B Latin America Exit: Sources
UnitedHealth Group Incorporated (NYSE:UNH) is one of the best Dow stocks to invest in. The company is considering several offers for its Latin American business, according to two insiders familiar with the situation, as it works to recover from a series of major setbacks, including the removal of its CEO and a reported criminal accounting investigation. The largest US health insurer has aimed to exit Latin America since 2022, but selling its Banmedica unit has become more urgent recently due to multiple challenges, one source said. A senior healthcare professional giving advice to a patient in a clinic. New CEO Steve Hemsley told shareholders last week that he is focused on regaining their confidence following a disappointing earnings report and a Wall Street Journal story about a criminal probe into alleged Medicare fraud. UnitedHealth Group Incorporated (NYSE:UNH) maintains it has not been notified by the Department of Justice and stands by its business integrity. UnitedHealth Group Incorporated (NYSE:UNH) has received four non-binding bids for Banmedica, which operates in Colombia and Chile, totaling around $1 billion, according to sources who requested anonymity due to the confidential nature of the negotiations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Stanford Health Care and Kivo Health Collaborate to Advance Value Based Care for COPD through Virtual Pulmonary Rehabilitation
PALO ALTO, Calif. & SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--Stanford Health Care, one of the nation's leading academic medical centers, tapped Kivo Health as part of a collaboration to advance AI-powered virtual pulmonary rehabilitation and care for patients with Chronic Obstructive Pulmonary Disease (COPD). As part of a broader initiative to deliver high-value care, Stanford Health Care is focused on delivering innovative care for common, costly, chronic conditions such as COPD. While pulmonary rehabilitation is the gold standard of care for COPD - resulting in 56% fewer hospitalizations and improved quality of life - fewer than 3% of those who could benefit, ever have access to this life altering intervention. By collaborating with Kivo Health, Stanford Health Care enables thousands of patients to complete pulmonary rehabilitation from the safety and comfort of their homes, improving outcomes for COPD patients, and keeping patients healthy and out of the hospital. "We are thrilled to collaborate with Kivo Health to bring virtual pulmonary rehabilitation to our COPD patients," said Leah Rosengaus, Senior Director of Digital Health at Stanford Health Care. "We are dedicated to enhancing access to care, and believe innovative solutions like virtual pulmonary rehabilitation provide patients with new channels to connect to services, and support healing in the comfort of home." "This collaboration reflects a bold commitment to evidence-based innovation, health equity, and value-based care," said Victor Sadauskas, MD, CEO of Kivo Health. "Together, we are transforming how COPD is managed—expanding access, improving outcomes, and dramatically reducing avoidable hospitalizations for one of the most underserved, highest-cost chronic conditions in the U.S." For more information about Stanford Health Care and Kivo Health, visit and About Stanford Health Care Stanford Health Care seeks to heal humanity through science and compassion, one patient at a time, through its commitment to care, educate and discover. Stanford Health Care delivers clinical innovation across its inpatient services, specialty health centers, physician offices, virtual care offerings and health plan programs. Stanford Health Care is part of Stanford Medicine, a leading academic health system that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children's Health, with Lucile Packard Children's Hospital. Stanford Medicine is renowned for breakthroughs in treating cancer, heart disease, brain disorders and surgical and medical conditions. For more information, visit: About Kivo Health Kivo Health provides AI-powered virtual rehab and care for people with COPD. Kivo's Medicare-covered program improves patient symptoms while reducing costs of care by keeping patients healthy and at home. View source version on Contacts Kivo HealthVictor Sadauskascontact@ Sign in to access your portfolio


Business Wire
an hour ago
- Business Wire
Stanford Health Care and Kivo Health Collaborate to Advance Value Based Care for COPD through Virtual Pulmonary Rehabilitation
PALO ALTO, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Stanford Health Care, one of the nation's leading academic medical centers, tapped Kivo Health as part of a collaboration to advance AI-powered virtual pulmonary rehabilitation and care for patients with Chronic Obstructive Pulmonary Disease (COPD). As part of a broader initiative to deliver high-value care, Stanford Health Care is focused on delivering innovative care for common, costly, chronic conditions such as COPD. While pulmonary rehabilitation is the gold standard of care for COPD - resulting in 56% fewer hospitalizations and improved quality of life - fewer than 3% of those who could benefit, ever have access to this life altering intervention. By collaborating with Kivo Health, Stanford Health Care enables thousands of patients to complete pulmonary rehabilitation from the safety and comfort of their homes, improving outcomes for COPD patients, and keeping patients healthy and out of the hospital. "We are thrilled to collaborate with Kivo Health to bring virtual pulmonary rehabilitation to our COPD patients," said Leah Rosengaus, Senior Director of Digital Health at Stanford Health Care. "We are dedicated to enhancing access to care, and believe innovative solutions like virtual pulmonary rehabilitation provide patients with new channels to connect to services, and support healing in the comfort of home.' 'This collaboration reflects a bold commitment to evidence-based innovation, health equity, and value-based care,' said Victor Sadauskas, MD, CEO of Kivo Health. 'Together, we are transforming how COPD is managed—expanding access, improving outcomes, and dramatically reducing avoidable hospitalizations for one of the most underserved, highest-cost chronic conditions in the U.S.' For more information about Stanford Health Care and Kivo Health, visit and About Stanford Health Care Stanford Health Care seeks to heal humanity through science and compassion, one patient at a time, through its commitment to care, educate and discover. Stanford Health Care delivers clinical innovation across its inpatient services, specialty health centers, physician offices, virtual care offerings and health plan programs. Stanford Health Care is part of Stanford Medicine, a leading academic health system that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children's Health, with Lucile Packard Children's Hospital. Stanford Medicine is renowned for breakthroughs in treating cancer, heart disease, brain disorders and surgical and medical conditions. For more information, visit: About Kivo Health Kivo Health provides AI-powered virtual rehab and care for people with COPD. Kivo's Medicare-covered program improves patient symptoms while reducing costs of care by keeping patients healthy and at home.